세계의 분자세포유전학 시장 : 제품 및 서비스별(키트, 시약, 프로브, 기기, 소프트웨어, 서비스), 기술별(FISH, CISH, CGH), 최종사용자별, 용도별(암, 유전성 질환) - 예측(-2028년)
Molecular Cytogenetics Market by Product (Kits, Reagents, Probes, Instrument, Software, Services), Technique (FISH, CISH, Comparative Genomic Hybridization (Array-based, Standard)), Application (Cancer, Genetics Disorders) - Global Forecast to 2028
상품코드:1419286
리서치사:MarketsandMarkets
발행일:2024년 01월
페이지 정보:영문 235 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
조사 범위
조사 대상 연도
2021-2028년
기준 연도
2022년
예측 기간
2023-2028년
검토 단위
금액(10억 달러)
부문
제품 및 서비스별, 기술별, 용도별, 최종사용자별, 지역별
대상 지역
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카
분자세포유전학 시장 규모는 2023년 31억 달러로 평가되며 예측 기간 동안 9.9%의 CAGR을 기록할 것으로 예상되며 2028년에는 49억 달러에 달할 것으로 전망됩니다.
암 및 유전성 질환과 같은 만성 질환의 발병률이 증가함에 따라 질병의 조기 진단과 질병의 핵심 원인에 대한 진단의 보급률이 증가하고 있습니다. 이러한 환자들을 관리하기 위해서는 긴급하고 시기적절한 치료가 필요합니다. 연구 및 진단 절차의 전반적인 증가는 질병의 정확한 진단을 보장하기 위해 분자세포유전학의 채택 증가로 이어지고 있습니다. 이는 전체 시장의 성장을 주도하고 있습니다.
분자세포유전학 시장의 키트 및 시약 부문은 암과 같은 질병의 발생률 증가와 개인 맞춤형 의료에 대한 관심 증가에 힘입어 큰 폭의 성장을 경험하고 있습니다.
분자세포유전학 시장의 비교 유전체 하이브리드화 분야는 임상 병리학 및 연구 분야에서 분자세포유전학의 보급이 증가함에 따라 크게 성장하고 있습니다.
현재 분자세포유전학 시장에서 가장 높은 성장률을 보이고 있는 분야는 암 분야입니다. 노령 인구의 증가와 유전자 변화로 인한 암 발생률 증가가 이 부문의 성장을 촉진하는 주요 요인으로 작용하고 있습니다.
2022년에는 임상 및 연구실 부문이 가장 높은 성장률을 기록했습니다. 이는 질병 진단을 위한 첨단 세포유전학 제품에 대한 수요 증가에 기인합니다.
아시아태평양은 예측 기간 동안 가장 높은 CAGR을 기록할 것으로 예상됩니다. 이 지역의 성장은 주로 중국과 일본에 집중될 것으로 예상됩니다. 고령 인구 증가, 암 발병률 증가, 의료비 지출 증가, 1인당 소득 증가, 첨단 기술에 대한 수요 증가, 아시아태평양 국가의 민간 의료 부문 확대, 빠른 속도로 성장하는 신흥 시장의 존재 등이 이 지역의 시장 개척을 주도하고 있습니다.
이 보고서는 세계 분자세포유전학 시장을 조사하여 제품/서비스별, 기술별, 용도별, 최종사용자별, 지역별 동향, 시장 진입 기업 개요 등을 정리하여 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 주요 인사이트
제5장 시장 개요
서론
시장 역학
가격 분석
특허 분석
무역 분석
밸류체인 분석
공급망 분석
생태계 분석
Porter's Five Forces 분석
PESTLE 분석
규제 분석
2022-2023년의 주요 회의와 이벤트
고객의 비지니스에 영향을 미치는 동향/혼란
주요 이해관계자와 구입 기준
사례 연구 분석
제6장 분자세포유전학 시장, 제품 및 서비스별
서론
키트·시약
기기
소모품
소프트웨어, 서비스
제7장 분자세포유전학 시장, 기술별
서론
CGH(Comparative Genomic Hybridization)
FISH(Fluorescent In Situ Hybridization)
CISH(Chromogenic In Situ Hybridization)
기타
제8장 분자세포유전학 시장, 용도별
서론
유전성 질환
암
맞춤형 의료
기타
제9장 분자세포유전학 시장, 최종사용자별
서론
임상 및 연구기관
학술연구기관
제약회사 및 바이오테크놀러지 회사
기타
제10장 분자세포유전학 시장, 지역별
서론
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
제11장 경쟁 상황
개요
주요 진출 기업 전략
시장 주요 진출 기업 매출 점유율 분석
시장 점유율 분석
기업 평가 매트릭스
스타트업/중소기업 평가 매트릭스
경쟁 시나리오와 동향
제12장 기업 개요
주요 진출 기업
F. HOFFMANN-LA ROCHE LTD.
DANAHER CORPORATION
AGILENT TECHNOLOGIES, INC.
ABBOTT LABORATORIES
THERMO FISHER SCIENTIFIC, INC.
ILLUMINA INC.
REVVITY
PACIFIC BIOSCIENCES
BIO-RAD LABORATORIES, INC.
BIO-TECHNE CORPORATION
GENEDX
ONCOCYTE CORPORATION
BIOVIEW
기타 기업
OXFORD GENE TECHNOLOGY IP LIMITED(PART OF SYSMEX)
APPLIED SPECTRAL IMAGING, INC.
CYTOTEST INC.
KROMATID, INC.
GENIAL GENETIC SOLUTIONS LTD.
CYTOGNOMIX, INC.
METASYSTEMS
SCIGENE
BIOMODAL
BIOCARE MEDICAL
BIODOT
ONCODNA
제13장 부록
ksm
영문 목차
영문목차
Report Description
Scope of the Report
Years Considered for the Study
2021-2028
Base Year
2022
Forecast Period
2023-2028
Units Considered
Value (USD) Billion
Segments
Product, technique, application, end user, and region
Regions covered
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
The molecular cytogenetics market is valued at an estimated USD 3.1 billion in 2023 and is projected to reach USD 4.9 billion by 2028, at a CAGR of 9.9% during the forecast period. Increasing in the incidence of chronic diseases like cancer and genetic diseases has lead to the increase in prevalence of the diagnosis of the diseases at earlier stage and diagnosis of the core cause of disease. Urgent and timely treatment is required to manage these patients. The overall increase in the number of research and diagnostic procedures is leading to the increased adoption of molecular cytogenetics in order to ensure theaccurate diagnosis of the diseases. This is driving the overall growth of the market.
"Kits & Reagents segment accounted for the highest growth rate in the molecular cytogenetics market, by product, during the forecast period."
The molecular cytogenetics market is bifurcated into kits & reagents, instruments, consumables and software & services on the basis of product. The kits & reagents segment in the molecular cytogenetics market is experiencing substantial growth, largely driven by the increasing incidence of diseases such as cancers and increasing focus on personalized medicines.
"Comparative genomic hybridization segment accounted for the highest growth rate in the molecular cytogenetics market, by technique, during the forecast period."
The molecular cytogenetics market is bifurcated into comparative genomic hybridization, fluorescence in-situ hybridization, chromogenic in-situ hybridization and other techniques on the basis of technique. The comparative genomic hybridization segment in the molecular cytogenetics market is experiencing substantial growth, largely driven by the increasing penetration of molecular cytogenetics in clinical pathology and research.
"Cancer segment accounted for the highest growth rate in the molecular cytogenetics market, by applications, during the forecast period."
The global molecular cytogenetics market is bifurcated into genetic disorders, cancer, personalized medicine and other applications. The cancer segment is currently witnessing the highest growth rate within the molecular cytogenetics market. The rising geriatric population and rising incidence of cancer due to genetic changes are the major factors driving this segment's growth.
"Clinical & research laboratories segment accounted for the highest CAGR"
Based on end users, the molecular cytogenetics market is segmented into clinical & research laboratories, academic research institutes, pharmaceutical & biotechnology companies and other end users. In 2022, the clinical & research laboratories segment accounted for the highest growth rate. This can be attributed to the increased demand for advanced cytogenetics products for disease diagnosis.
"Asia Pacific: The fastest-growing region molecular cytogenetics market"
The global molecular cytogenetics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Anticipated growth in this region will primarily focus on China and Japan. Factors such as a growing elderly population, rising cancer prevalence, increased healthcare expenditures, higher per capita income, escalating demand for advanced technology, the expansion of private healthcare sectors across several APAC nations, and the existence of rapidly developing markets are steering the market's growth in this region.
The break-up of the profile of primary participants in the molecular cytogenetics market:
By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
By Designation: C-level - 27%, D-level - 18%, and Others - 55%
By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%
The key players in this market are Thermo Fisher Scientific Inc. (US), Illumina Inc. (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), Abbott Laboratories (US), Agilent Technologies, Inc. (US), Pacific Biosciences (US), Bio-Rad Laboratories, Inc. (US), Bio-Techne Corporation (US), GeneDx (US), Oncocyte Corporation (US), BioView (Israel), Oxford Gene Technology IP, Limited. (UK), Applied Spectral Imaging, Inc. (US), Cyto-Test Inc. (US), KromaTiD, Inc. (US), Genial Genetic Solutions, Ltd. (UK), Cytognomix, Inc. (Canada), MetaSystems (Germany), SciGene (US), Biomodal (UK), Biocare Medical (US), BioDot (US), OncoDNA (Belgium).
Research Coverage:
This research report categorizes the molecular cytogenetics market by product (kits & reagents, instruments, consumables and software & services), technique (comparative genomic hybridization, fluorescence in-situ hybridization, chromogenic in-situ hybridization and other techniques), application (genetic disorders, cancer, personalized medicine and other applications), end user (clinical & research laboratories, academic research institutes, pharmaceutical & biotechnology companies and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities and challenges, influencing the growth of the molecular cytogenetics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions and services, key strategies, acquisitions, and agreements. New product launches and recent developments associated with the molecular cytogenetics market. Competitive analysis of upcoming startups in the molecular cytogenetics market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall molecular cytogenetics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (increasing incidence of cancer and genetic disorders, growing focus on targeted cancer treatment, rapid growth in aging population and subsequent increase in prevalence of chronic diseases, increasing penetration of molecular cytogenetics in clinical pathological testing), restraints (high cost of advanced instruments, unfavorable reimbursement scenario), opportunities (untapped emerging markets in Asia) and challenges (transition from FISH to array-based techniques) influencing the growth of the molecular cytogenetics market.
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular cytogenetics market.
Market Development: Comprehensive information about lucrative markets - the report analyses the molecular cytogenetics market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular cytogenetics market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Agilent Technologies, Inc. (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), among others in the molecular cytogenetics market strategies.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 MOLECULAR CYTOGENETICS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
TABLE 126 OTHER DEVELOPMENTS (JANUARY 2020-NOVEMBER 2023)
12 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) **
12.1 KEY PLAYERS
12.1.1 F. HOFFMANN-LA ROCHE LTD.
TABLE 127 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 34 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
12.1.2 DANAHER CORPORATION
TABLE 128 DANAHER CORPORATION: COMPANY OVERVIEW
FIGURE 35 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
12.1.3 AGILENT TECHNOLOGIES, INC.
TABLE 129 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
FIGURE 36 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
12.1.4 ABBOTT LABORATORIES
TABLE 130 ABBOTT LABORATORIES: COMPANY OVERVIEW
FIGURE 37 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
12.1.5 THERMO FISHER SCIENTIFIC, INC.
TABLE 131 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW
FIGURE 38 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
12.1.6 ILLUMINA INC.
TABLE 132 ILLUMINA INC.: COMPANY OVERVIEW
FIGURE 39 ILLUMINA INC.: COMPANY SNAPSHOT (2022)
12.1.7 REVVITY
TABLE 133 REVVITY: COMPANY OVERVIEW
FIGURE 40 REVVITY: COMPANY SNAPSHOT (2022)
12.1.8 PACIFIC BIOSCIENCES
TABLE 134 PACIFIC BIOSCIENCES: COMPANY OVERVIEW
FIGURE 41 PACIFIC BIOSCIENCES: COMPANY SNAPSHOT (2022)
12.1.9 BIO-RAD LABORATORIES, INC.
TABLE 135 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
FIGURE 42 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
12.1.10 BIO-TECHNE CORPORATION
TABLE 136 BIO-TECHNE CORPORATION: COMPANY OVERVIEW
FIGURE 43 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2022)
12.1.11 GENEDX
TABLE 137 GENEDX: COMPANY OVERVIEW
FIGURE 44 GENEDX: COMPANY SNAPSHOT (2022)
12.1.12 ONCOCYTE CORPORATION
TABLE 138 ONCOCYTE CORPORATION: COMPANY OVERVIEW
FIGURE 45 ONCOCYTE CORPORATION: COMPANY SNAPSHOT (2022)
12.1.13 BIOVIEW
TABLE 139 BIOVIEW: COMPANY OVERVIEW
12.2 OTHER PLAYERS
12.2.1 OXFORD GENE TECHNOLOGY IP LIMITED (PART OF SYSMEX)
12.2.2 APPLIED SPECTRAL IMAGING, INC.
12.2.3 CYTOTEST INC.
12.2.4 KROMATID, INC.
12.2.5 GENIAL GENETIC SOLUTIONS LTD.
12.2.6 CYTOGNOMIX, INC.
12.2.7 METASYSTEMS
12.2.8 SCIGENE
12.2.9 BIOMODAL
12.2.10 BIOCARE MEDICAL
12.2.11 BIODOT
12.2.12 ONCODNA
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
